Table 2.
Risk factors associated with VF and DRMs among HIV-1-positive patients treated with first-line ARV regimens in Gabon
| Variables | VF | Pa | Pb | DRM≥1 | Pa | Pb | ||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| VL<1000 cp/ml (N=220) | VL≥1000 cp/ml (N=155) | No (N=61) | Yes (N=80) | |||||
| Sex, n (%) | 0.24 | – | 0.95 | – | ||||
| Male | 63 (63.6) | 36 (36.4) | 14 (43.8) | 18 (56.2) | ||||
| Female | 157 (56.9) | 119 (43.1) | 47 (43.1) | 62 (56.9) | ||||
| Age (years), median (IQR) | 42.1 (36.8–50.2) | 42.3 (35.3–47.9) | 0.17 | 0.3 | 42.4 (34.4–47.0) | 41.6 (35.8–48.0) | 0.22 | – |
| Time on ART (years), median (IQR) | 32.9 (21.3–48.8) | 33.1 (20.4–52.9) | 0.4 | 24.1 (17.5–40.0) | 42.4 (25.2–57.9) | 0.012 | 0.00008 | |
| HIV care centre, n (%) | 0.01 | 0.0033 | 0.083 | 0.021 | ||||
| Rural | 54 (72.0) | 21 (28.0) | 5 (25.0) | 15 (75.0) | ||||
| Semirural | 166 (55.3) | 134 (44.7) | 56 (46.3) | 65 (53.7) | ||||
| Unstructured treatment interruptions, n (%) | <0.0001 | 0.044 | 0.14 | 0.34 | ||||
| No | 149 (70.0) | 64 (30.0) | 28 (50.9) | 27 (49.1) | ||||
| Yes | 71 (43.8) | 91 (56.2) | 33 (38.4) | 53 (61.6) | ||||
| CD4+ count at ART initiation, median, cells/µl | ||||||||
| (IQR) | 161 (69–250) | 157 (80–240) | 0.9 | – | 156 (94–245) | 122 (54–237) | 0.33 | – |
| CD4+ count at enrolment, median, cells/µl | ||||||||
| (IQR) | 412 (295–566) | 229 (120–350) | <0.0001 | <0.0001 | 232 (139–349) | 213 (110–309) | 0.42 | – |
| HIV-1 RNA VL (log10 cp/ml), median (IQR) | – | – | – | – | 5.14 (3.98–5.83) | 4.98 (4.19–5.66) | 0.74 | – |
a
Univariate analysis
b
Multivariate analysis.
Abbreviations: VL, viral load; VF, virological failure; DRM, drug resistance mutation; ART, antiretroviral treatment; IQR, interquartile range.